publication venue for
- Long-Term Follow-up of Tisagenlecleucel in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Updated Analysis of Juliet Study 2019
- Prolonged Improvement in Patient Reported Quality of Life (QoL) Following Tisagenlecleucel Infusion in Adult Patients (pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL): 19-Month Follow-up (FU) of the Juliet Study 2019
- Remission to Transplantation Time in Acute Myeloid Leukemia 2019
- Study Design of a Phase 3, Randomized, Open-Label, Multicenter Study to Evaluate Ruxolitinib Over BAT in Patients with Corticosteroid-Refractory Chronic Graft vs Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation (REACH-3) 2018
- Carmustine-Free Conditioning Regimens Offer Comparable Efficacy to BEAM: The First Report of the Canadian Blood and Marrow Transplant Group Registry 2016
- Th17 Recruitment and Interferon Pathway Activation in Oral Chronic Graft-Versus-Host Disease Tissues 2016
- Treatment of Severe Relapsing-Remitting Multiple Sclerosis with High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation: 2-Year Follow-up Results of the HALT MS Clinical Trial (Immune Tolerance Network: ITN033AI) 2013
- Cyclosporine Area Under the Curve in Children Undergoing Haematopoietic Stem Cell Transplantation: Limited Sampling Strategy at Steady-State 2012
- Hematopoietic Stem Cell Transplantation (HSCT) in Infants 2011
- Hypertension in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Patients 2011
- 179: Unrelated donor umbilical cord blood transplant following intrauterine transfusions for treatment of alpha thalassemia major 2007
- Glycogen synthase kinase-3 is an in vivo regulator of human hemopoietic stem cells 2006
- Preemptive therapy with ganciclovir and short-course intravenous immunoglobulin does not prevent recurrent cytomegalovirus infection (CBMTG-102 study) 2005
- Canadian pilot trial of haplo-identical donor transplantation 2004
- Early Mixed Donor Chimerism is a Strong Negative Prognostic Indicator in Allogeneic Stem Cell Transplant for AML and MDS.. S2666-6367(24)00759-0. 2024
- Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients in the Maintenance Era: Real-World Results from The Canadian Myeloma Research Group Database. 30:889-901. 2024
- Durable Efficacy and Manageable Safety in Patients Age ≥75 Years with Relapsed/Refractory Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Real-World Setting. 30:S187-S188. 2024
- Real-World Tisagenlecleucel Outcomes in Richter-Transformed Chronic Lymphocytic Leukemia: A Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis. 30:S189-S190. 2024
- Rituximab Toxicity after Preemptive or Therapeutic Administration for Post-Transplant Lymphoproliferative Disorder. 29:43.e1-43.e8. 2023
- Recognition of Hematopoietic Stem Cell Transplantation and Cellular Therapy Expertise to Promote Care Accessibility: A Formally Credentialed Area of Focused Competence in Canada. 27:702-706. 2021
- Home Spirometry Telemonitoring for Early Detection of Bronchiolitis Obliterans Syndrome in Patients with Chronic Graft-versus-Host Disease. 27:616.e1-616.e6. 2021
- Continuous Alloreactive T Cell Depletion and Regulatory T Cell Expansion for the Treatment of Steroid- Refractory or Dependent Chronic GVHD – a Multicentre Phase II Clinical Trial (CARE Trial). 27:S285-S285. 2021
- Anti-Thymocyte Globulin Prophylaxis Induces a Decrease in Naive Th Cells to Inhibit the Onset of Chronic Graft-versus-Host Disease: Results from the Canadian Bone Marrow Transplant Group (CBMTG) 0801 Study. 26:438-444. 2020
- Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis. 24:2360-2364. 2018
- Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75. 24:2157-2159. 2018
- CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation. 23:405-411. 2017
- Erratum to “Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group Study” [Biol Blood Marrow Transplant 2016;22:1410-1415]. 23:534-534. 2017
- Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group Study. 22:1410-1415. 2016
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report. 21:1343-1359. 2015
- Favorable Outcomes from Allogeneic and Autologous Stem Cell Transplantation for Patients with Transformed Nonfollicular Indolent Lymphoma. 20:1813-1818. 2014
- National Institutes of Health Chronic Graft-versus-Host Disease Staging in Severely Affected Patients: Organ and Global Scoring Correlate with Established Indicators of Disease Severity and Prognosis. 19:632-639. 2013
- Prediction of Area under the Cyclosporine Concentration Versus Time Curve in Children Undergoing Hematopoietic Stem Cell Transplantation. 19:418-423. 2013
- Costs and Cost-Effectiveness of Allogeneic Stem Cell Transplantation in Children Are Predictable. 18:1533-1539. 2012
- Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma. 14:775-782. 2008
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group Report. 12:491-505. 2006
- Long-Term Survival after Blood and Marrow Transplantation: Comparison with an Age- and Gender-Matched Normative Population. 12:422-429. 2006
- An evaluation of the donor experience in the canadian multicenter randomized trial of bone marrow versus peripheral blood allografting. 10:405-414. 2004
- Renal pathology at autopsy in patients who died after hematopoietic stem cell transplantation. 9:683-688. 2003
- Renal pathology at autopsy in patients who died after hematopoietic stem cell transplantation.. 9:683-688. 2003
- Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells. 9:312-319. 2003
- Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. 6:628-632. 2000